Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity

被引:57
|
作者
Zafrani, L. [1 ,2 ]
Mariotte, E. [1 ,2 ]
Darmon, M. [3 ,4 ]
Canet, E. [1 ,2 ]
Merceron, S. [1 ,2 ]
Boutboul, D. [2 ,5 ]
Veyradier, A. [6 ]
Galicier, L. [2 ,5 ]
Azoulay, E. [1 ,2 ]
机构
[1] Hop St Louis, AP HP, Med Intens Care Unit, Paris, France
[2] Paris Diderot Univ, Paris, France
[3] St Etienne Univ Hosp, Med Surg Intens Care Unit, St Etienne, France
[4] Univ St Etienne, St Etienne, France
[5] Hop St Louis, AP HP, Dept Clin Immunol, Paris, France
[6] Antoine Beclere Hosp, Dept Hematol, Clamart, France
关键词
acute kidney injury; ADAMTS13; protein; human; complement system proteins; renal replacement therapy; thrombotic thrombocytopenic purpura; VON-WILLEBRAND-FACTOR; HEMOLYTIC-UREMIC SYNDROME; FACTOR-CLEAVING PROTEASE; ACUTE KIDNEY INJURY; COMPLEMENT ACTIVATION; ORGAN DYSFUNCTION; DEFICIENCY; MICROANGIOPATHIES; DEFINITION; EXPERIENCE;
D O I
10.1111/jth.12826
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundAmong patients with thrombotic microangiopathies, acute kidney injury (AKI) is the hallmark of hemolytic uremic syndrome (HUS) and is largely underestimated in patients with thrombotic thrombocytopenic purpura (TTP). ObjectiveWe sought to report AKI features and outcomes in patients with TTP. MethodsWe conducted a retrospective study of 92 patients with TTP assessed by low ADAMTS13 activity (<10%) between 2001 and 2013. A logistic regression identified variables independently associated with AKI. ResultsAmong the 92 patients, 54 (58.7%) presented with AKI, including 25 (46.3%) with stage 3 AKI. Fourteen (27.4%) patients had a nephrotic-range proteinuria and 21 (45.6%) had hemoglobinuria. Hematuria and leucocyturia were detected in 19 (41.3%) and 16 patients (36.4%), respectively. Renal replacement therapy (RRT) was required in 14 patients (25.9%). Six months after TTP remission, RRT-free patients had median (IQR) MDRD (Modification of Diet in Renal Disease formula estimating the glomerular filtration rate) of 93mLmin(-1) per 1.73m(2) (68.8-110) and three patients required long-term dialysis. Mild or moderate chronic renal disease occurred in 23/54 (42.6%) AKI patients. By multivariate analysis, serum level of complement component 3 at admission was the only factor independently associated with AKI (OR per 0.25 unit decrease of C3, 0.85; CI, 1.82-8.33; P=0.001). ConclusionsIn patients with TTP, AKI is present in more than half the patients, and half of those will have lasting renal effects. Further studies to better understand the pathophysiology of renal involvement in patients with TTP and to identify a subset of patients with TTP syndrome overlapping HUS are warranted.
引用
收藏
页码:380 / 389
页数:10
相关论文
共 50 条
  • [21] Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura
    Bendapudi, Pavan K.
    Foy, Brody H.
    Mueller, Sarah B.
    Liu, Jun
    Feingold, Louis M.
    Burke, Kristen E.
    Cruz, Wendy
    Chen, Maria Y.
    Lau, Emily S.
    Goldberg, Rachel L.
    Tatake, Ishan
    Wilkinson, Shelby C.
    Carney, Brian J.
    Stone, James R.
    Park, Doyun
    Avelino, Alzira R.
    Hassan, Sajjad
    Andrzejewski, Chester
    Ruby, Kristen N.
    Friedman, Kenneth D.
    Brunker, Patricia A. R.
    Leaf, Rebecca K.
    Higgins, John
    Dzik, Walter H.
    Stefely, Jonathan A.
    Makar, Robert S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (18) : 1690 - 1698
  • [22] Current and Future Perspectives on ADAMTS13 and Thrombotic Thrombocytopenic Purpura
    Roose, Elien
    Joly, Berangere S.
    HAMOSTASEOLOGIE, 2020, 40 (03): : 322 - 336
  • [23] Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura
    Yamaguchi, Yusuke
    Moriki, Takanori
    Igari, Atsuko
    Nakagawa, Terumichi
    Wada, Hideo
    Matsumoto, Masanori
    Fujimura, Yoshihiro
    Murata, Mitsuru
    THROMBOSIS RESEARCH, 2011, 128 (02) : 169 - 173
  • [24] ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy
    Raman, Rachna
    Yang, Shangbin
    Wu, Haifeng M.
    Cataland, Spero R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (02) : 277 - 278
  • [25] Seasonal distribution of severe ADAMTS13 deficient idiopathic thrombotic thrombocytopenic purpura
    Raval, Jay S.
    Harm, Sarah K.
    Rollins-Raval, Marian A.
    Kiss, Joseph E.
    JOURNAL OF CLINICAL APHERESIS, 2014, 29 (02) : 113 - 119
  • [26] Validation of a panel of ADAMTS13 assays for diagnosis of thrombotic thrombocytopenic purpura: activity, functional inhibitor, and autoantibody test
    Nakashima, M. O.
    Zhang, X.
    Rogers, H. J.
    Vengal, L.
    Gibson, B.
    Daly, T. M.
    Kottke-Marchant, K.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 (05) : 550 - 559
  • [27] Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura
    Connell, Nathan T.
    Cheves, Tracey
    Sweeney, Joseph D.
    TRANSFUSION, 2016, 56 (02) : 354 - 359
  • [28] ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment
    Rurali, Erica
    Banterla, Federica
    Donadelli, Roberta
    Bresin, Elena
    Galbusera, Miriam
    Gastoldi, Sara
    Peyvandi, Flora
    Underwood, Mary
    Remuzzi, Giuseppe
    Noris, Marina
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 10 (11): : 2002 - 2012
  • [29] Practical Issues in ADAMTS13 Testing and Emerging Therapies in Thrombotic Thrombocytopenic Purpura
    Cataland, Spero R.
    Wu, Haifeng M.
    SEMINARS IN HEMATOLOGY, 2011, 48 (04) : 242 - 250
  • [30] Successful management of pregnancy-associated thrombotic thrombocytopenic purpura by monitoring ADAMTS13 activity
    Yamashita, Eriko
    Okada, Hidetaka
    Yorioka, Hirokazu
    Fujita, Shinya
    Nishi, Kenichiro
    Komiyama, Yutaka
    Kanzaki, Hideharu
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2012, 38 (03) : 567 - 569